EC[ON]OMY

Lessons for Kazakhstan: Patent Challenges in Pharma

Patent disputes have become a major obstacle to medicine accessibility. The U.S., as a leader in the pharmaceutical industry, faces challenges from expanding patent portfolios. This trend delays the release of generics and biosimilars. Kazakhstan, developing its pharmaceutical market, may encounter similar challenges.

In the U.S. original drugs are often protected by dozens, sometimes hundreds, of patents. A notable example is Humira. The primary compound patent for this drug expired in 2016. However, AbbVie obtained over 160 additional patents. These patents extended the drug’s monopoly until 2037. As a result, the market remained closed to biosimilars for two decades.

The issue is not just the number of patents. Generic manufacturers must challenge each patent in court. On average, a single drug is protected by numerous patents, each with multiple claims. Companies must win dozens of lawsuits to bring their products to market. The financial and time burden makes this process nearly impossible for many players.

This situation significantly reduces medicine accessibility for patients. Generics and biosimilars are typically much cheaper than original drugs. For example, in the past decade, generics have saved the U.S. healthcare system about $3 trillion. However, patent barriers limit these savings.

Kazakhstan, with its growing local production, must consider this experience. An increase in local manufacturers will inevitably lead to more patent disputes. Mechanisms must be created to balance the interests of patent holders and patients. For example, policies on issuing additional patents for minor changes to drugs should be revised. This would prevent artificial extensions of monopolies.

The U.S. system also struggles with “patent thickets.” This practice allows original drug manufacturers to delay generic entry through patent disputes. For instance, new patent applications are often filed in the final years of the primary patent’s validity. Kazakhstan can develop laws to limit such practices. This would accelerate the introduction of more affordable medicines to the market.

Another important aspect is the incentives for generic and biosimilar manufacturers. In the U.S. companies developing these drugs often invest millions in patent disputes. Kazakhstan must create a more accessible legal and regulatory environment. This could include simplifying registration processes and reducing bureaucratic barriers.

The key takeaway from the U.S. experience is the need for balance. Intellectual property protection should stimulate innovation but not hinder competition. Kazakhstan can implement a more flexible regulatory system. This would ensure medicine accessibility for patients and fair working conditions for manufacturers.

Patent barriers are not just about medicine costs. They are also about time. In the U.S., court proceedings often take years. Generic manufacturers delay the launch of their products, waiting for court decisions. Kazakhstan can develop mechanisms for expedited dispute resolution to shorten these timelines.

Patent barriers affect not only the pharmaceutical industry but also public health. The longer affordable medicines are delayed, the more patients go untreated. For Kazakhstan, this issue is especially critical given limited healthcare budgets.

The U.S. experience shows that solving these problems requires a comprehensive approach. Changes in legislation, the development of local industries, and incentives for competition are needed. Kazakhstan can avoid U.S. mistakes by adopting best practices and tailoring them to its realities.

 

Prepared by: Guldariya Manakpaeva, Executive Director of the “PharmMedIndustry Kazakhstan” Association, specifically for http://www.economyKZ.org
 

Scroll to Top